In Vivo Dosimetry for BNCT

Johanna Karila, Carita Aschan, Tom Seren, Mika Kortesniemi, Petri Kotiluoto, Tiina Seppälä, Matti Toivonen, Leena Kankaanranta, Heikki Joensuu, Iiro Auterinen, Sauli Savolainen

    Research output: Chapter in Book/Report/Conference proceedingConference article in proceedingsScientific


    A phase I BNCT trial in glioblastoma started at the Finnish BNCT facility in May 1999. The aim of the present work was to verify the doses calculated in treatment planning and estimate the whole body dose on the basis of neutron fluence and gamma dose measurements in vivo and in a whole body phantom. Neutron fluence and gamma dose measurements were made with 55Mn activation foils and 7LiF:Mg,Cu,P TL detectors, respectively. Detector pairs or gamma detectors alone were placed on the patients (entrance surface and accessible upper body cavities) and in a modified water-filled whole body phantom. The calculated and measured neutron fluences and absorbed gamma doses correlated well within the uncertainties in the phantom measurements as well as in the patient measurements. Despite the different alignment of the two treatment fields in the head, the measured body doses have been approximately the same in all patients, e.g. in the umbilicus 40 plus/minus 10 mGy.
    Original languageEnglish
    Title of host publicationProgram & Abstracts of 9th International Symposium on Neutron Capture Therapy for Cancer
    Place of PublicationOsaka
    Publication statusPublished - 2000
    MoE publication typeB3 Non-refereed article in conference proceedings
    Event9th International Symposium on Neutron Capture Therapy for Cancer: NCT Osaka 2000 - Osaka, Japan
    Duration: 2 Oct 20006 Oct 2000


    Conference9th International Symposium on Neutron Capture Therapy for Cancer


    Dive into the research topics of 'In Vivo Dosimetry for BNCT'. Together they form a unique fingerprint.

    Cite this